Template:Hormone levels with transdermal estradiol patches

From blackwiki
Jump to navigation Jump to search
Template documentation

See also

References

  1. "Prescribing Information: Vivelle (estradiol transdermal system)" (PDF). U.S. Food and Drug Administration.
  2. "Prescribing Information: VIVELLE-DOT (estradiol transdermal system)" (PDF). U.S. Food and Drug Administration.
  3. "Estradiol patch". Daily Med. U.S. National Library of Medicine.
  4. "Climara (estradiol transdermal system)" (PDF). U.S. Food and Drug Administration.
  5. "Menostar (estradiol transdermal system)" (PDF). U.S. Food and Drug Administration.
  6. "ESTRADIOL patch". Daily Med. U.S. National Library of Medicine.
  7. "Climara Forte". HPRA. Retrieved 22 December 2018.
  8. Shah VP, Maibach HI (29 June 2013). Topical Drug Bioavailability, Bioequivalence, and Penetration. Springer Science & Business Media. pp. 47–50. ISBN 978-1-4899-1262-6.
  9. 9.0 9.1 9.2 C. Christian; B. von Schoultz (15 March 1994). Hormone Replacement Therapy: Standardized or Individually Adapted Doses?. CRC Press. pp. 9–16, 60. ISBN 978-1-85070-545-1. The mean integrated estradiol level during a full 28-day normal cycle is around 80 pg/ml.
  10. 10.0 10.1 10.2 Smith RD, Robinson DE, Delignieres B, Albertson BD, Tomai TP, Zinaman MJ, Simon JA (December 1991). "Effects of vehicle supplementation on total estradiol absorption from a transdermal estradiol delivery system". Fertil. Steril. 56 (6): 1029–33. doi:10.1016/S0015-0282(16)54712-8. PMID 1743317.
  11. Ockrim JL, Lalani EN, Laniado ME, Carter SS, Abel PD (May 2003). "Transdermal estradiol therapy for advanced prostate cancer--forward to the past?". J. Urol. 169 (5): 1735–7. doi:10.1097/01.ju.0000061024.75334.40. PMID 12686820.
  12. Langley RE, Godsland IF, Kynaston H, Clarke NW, Rosen SD, Morgan RC, Pollock P, Kockelbergh R, Lalani EN, Dearnaley D, Parmar M, Abel PD (August 2008). "Early hormonal data from a multicentre phase II trial using transdermal oestrogen patches as first-line hormonal therapy in patients with locally advanced or metastatic prostate cancer". BJU Int. 102 (4): 442–5. doi:10.1111/j.1464-410X.2008.07583.x. PMC 2564109. PMID 18422771.
  13. Ockrim J, Lalani EN, Abel P (October 2006). "Therapy Insight: parenteral estrogen treatment for prostate cancer--a new dawn for an old therapy". Nat Clin Pract Oncol. 3 (10): 552–63. doi:10.1038/ncponc0602. PMID 17019433.
  14. 14.0 14.1 Re I, Asenjo G, Maximino G, Micheletti L (2005). "Tratamiento del Cáncer de Próstata Avanzado con Estrógenos Transdérmicos Escrotales (ETE)" [Transdermal Scrotal Estrogen Patches (TSEP) in the Treatment of Advanced Prostate Cancer]. Revista Argentina de Urología (in Spanish). 70 (4): 231. ISSN 0325-2531.